1. Aliskiren: Preclinical evidence for the treatment of hyperproliferative skin disorders.
- Author
-
Pawloski PL, Moreira CG, Horinouchi CDS, Fernandes D, Olchanheski LR Júnior, Machado W, Cabrini DA, Dietrich M, Paludo K, and Otuki MF
- Subjects
- Angiotensin II pharmacology, Animals, Anti-Inflammatory Agents pharmacology, Cardiovascular System drug effects, Cardiovascular System metabolism, Disease Models, Animal, Female, Inflammation drug therapy, Inflammation metabolism, Keratinocytes drug effects, Keratinocytes metabolism, Mice, Psoriasis drug therapy, Psoriasis metabolism, Renin metabolism, Renin-Angiotensin System drug effects, Skin Diseases metabolism, Amides pharmacology, Antihypertensive Agents pharmacology, Fumarates pharmacology, Skin Diseases drug therapy
- Abstract
Psoriasis is a complex inflammatory and hyperproliferative skin disease. The pathogenesis and mechanisms involved are not completely understood, which makes treatment a difficult issue. Angiotensin II, the most active peptide of the renin-angiotensin system, seems to be involved in processes related to psoriasis pathogenesis, such as inflammation and cell proliferation. The aim of this study was to investigate the influence of renin inhibition on inflammation parameters and keratinocyte proliferation in a mouse model of chronic skin inflammation induced by croton oil. Aliskiren had anti-inflammatory effects by reducing levels of tumor necrosis factor-α and interleukin -6, and by inhibiting myeloperoxidase activity. Aliskiren also showed antiproliferative activity by reducing epidermal hyperplasia and proliferating cell nuclear antigen levels. Aliskiren treatment did not induce alterations in the cardiovascular system, normal skin thickness, and organ weight. These results suggest that aliskiren could be a valuable tool to be incorporated in the treatment of hyperproliferative and inflammatory skin disorders such as psoriasis., (Copyright © 2018 Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF